Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis (PRIGA)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by Fundacion Clinic per a la Recerca Biomédica
Information provided by (Responsible Party):
Sara Varea, Fundació Clínic per la Recerca Biomèdica Identifier:
First received: March 27, 2012
Last updated: October 20, 2014
Last verified: October 2014

This is a study to evaluate the primovist as a new contrast agent useful to diagnostic of hepatocellular carcinoma

Condition Intervention Phase
Hepatocellular Carcinoma
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis

Resource links provided by NLM:

Further study details as provided by Fundacion Clinic per a la Recerca Biomédica:

Primary Outcome Measures:
  • hepatocellular carcinoma diagnosed [ Time Frame: 1 month ] [ Designated as safety issue: No ]
    Proportion of hepatocellular carcinoma diagnosed using gadoxetic acid magnetic resonance imaging (accuracy for diagnosis)

Secondary Outcome Measures:
  • magnetic resonance imaging sensitivity [ Time Frame: 9 months ] [ Designated as safety issue: No ]

    magnetic resonance imaging sensitivity - number of patients that need fine-needle biopsy to the diagnosis.

    the patients would be followed until the diagnosis would be stablished. Is expected that this would be before 9 months.

Estimated Enrollment: 70
Study Start Date: July 2012
Estimated Study Completion Date: April 2015
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Is a non comparative study. a magnetic resonance will be done using gadoxetic acid : 0.025mmol/Kg
all patients will have a magnetic resonance with gadobutrol as reference for diagnosis; in participants an additional magnetic resonance will be done with the new contrast agent to verify if the diagnostic can be done.

Detailed Description:

The investigators plan to define the imaging patterns of hepatocellular carcinoma in cirrhotic patients when studied with gadoxetic acid magnetic resonance imaging including the dynamic phase and the hepatobiliary phase at 10 and 20 minutes after contrast injection and to evaluate the usefulness of liver magnetic resonance imaging with gadoxetic acid in the differentiation between benign and malignant nodules in the cirrhotic liver. To determine the diagnosis and clinical significance of the infracentimetric additional nodules detected in the hepatobiliary phase


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • more than 18 years old
  • patient with diagnosis of liver cirrhosis Child Pugh A-B
  • Patients without previous hepatocellular carcinoma in whom ultrasound detects a suspicious hepatic lesion; solitary solid and well-defined nodule between 10 and 20mm
  • patients in whom diagnosis of hepatocellular carcinoma is a clinical need prior to treatment indication
  • patient that agree to participate signing informed consent form

Exclusion Criteria:

  • Patients with poor liver function who would have undergone transplantation even without hepatocellular carcinoma diagnosis (Child-Pugh C)
  • patients with previous diagnosis of hepatocellular carcinoma
  • patients with significant comorbidities that could prevent the optimum therapeutic decision in case of positive diagnosis of hepatocellular carcinoma
  • patients with severe clotting alterations that contraindicate the fine-needle biopsy -Patients with chronic kidney disease or glomerular filtration rate < 30 ml/min
  • patients with contraindications to perform magnetic resonance imaging (pacemaker, claustrophobia...)
  • Known hypersensitivity to study drugs or excipients
  • pregnancy or breastfeeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01575574

Contact: Carmen Ayuso, Prof, PhD, MD +34932275735
Contact: Sara Varea, B Sc +34932275400 ext 3343

Hospital Clinic of Barcelona Recruiting
Barcelona, Spain, 08036
Contact: Carmen Ayuso, MD PhD Prof   
Principal Investigator: Carmen Ayuso, MD phD Prof         
Sponsors and Collaborators
Sara Varea
Principal Investigator: Carmen Ayuso, Prof, PhD MD Hospital Clínic of Barcelona
  More Information

No publications provided

Responsible Party: Sara Varea, Clinical Research Manager, Fundació Clínic per la Recerca Biomèdica Identifier: NCT01575574     History of Changes
Other Study ID Numbers: PRIGA, 2011-005909-79
Study First Received: March 27, 2012
Last Updated: October 20, 2014
Health Authority: Spain: Spanish Agency of Medicines

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Liver Cirrhosis
Digestive System Diseases
Digestive System Neoplasms
Liver Diseases
Liver Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Gadolinium ethoxybenzyl DTPA
Contrast Media
Diagnostic Uses of Chemicals
Pharmacologic Actions processed this record on November 25, 2014